Mark R. Herbert, Interim PresidentMark R. Herbert is Interim President of Arcturus Therapeutics Ltd. Mr. Herbert joined Arcturus in 2015, and previously served as Vice President of Business Development and Alliance Management. He previously was Head of U.S. Business Development and Sales at STA Pharmaceutical Co., Ltd., WuXi AppTec’s small molecule development and manufacturing division, where he was responsible for all North American business development and marketing activities. Prior to WuXi AppTec, Mr. Herbert served as Director of Pharmaceutical Sciences at Aragon Pharmaceuticals, Inc. which was acquired by Johnson & Johnson in 2013. Mr. Herbert’s background includes over 15 years of experience in business and technical development of large and small molecules working across a number of different platforms and therapeutic areas. He is an author or inventor on over 35 peer-reviewed manuscripts and patents and has led or contributed to the submission of 13 investigational new drug (IND) applications and one new drug application (NDA).
Christine Esau, Vice President of Research and DevelopmentChristine Esau joined Arcturus in 2015 and serves as Vice President of Research and Development. She most recently served as Arcturus’ Senior Director of Translational Research. Dr. Esau was previously lead biologist at Ionis Pharmaceuticals and Regulus Therapeutics and served as Chief Scientific Officer of AptamiR Therapeutics. She has performed pioneering work in microRNA biology and anti-miRNA targeting technology development, resulting in landmark, highly cited papers and early patent filings. As lead biologist for the anti-miR-122 program for treatment of HCV with Regulus, she moved the program from discovery biology to lead compound selection, directing pharmacology, PK/PD, safety, and mechanism of action studies. At Regulus, she led exploratory efforts to identify novel microRNA targets for metabolic diseases, in the process establishing an extensive network of academic collaborators. Dr. Esau led the anti-miR-33 program for atherosclerosis which came out of these efforts and was the basis for Regulus’ partnership with Astra-Zeneca. While Chief Scientific Officer of AptamiR Therapeutics, Dr. Esau worked to develop a microRNA based therapy for the treatment of obesity. Dr. Esau earned a B.S. degree in biology from the California Institute of Technology and a Ph.D. from the Massachusetts Institute of Technology.
Rebecque Laba, Vice President of Finance and OperationsRebecque Laba joined Arcturus in August 2017 and serves as Vice President of Finance and Operations. Ms. Laba was previously Vice President, Finance and Corporate Operations at Celladon Corporation where she led the company through a successful IPO and raised over $100MM in private equity and debt. Prior to Celladon Ms. Laba served as Senior Director, Finance and Administration at Idun Pharmaceuticals which was acquired by Pfizer in 2005. Ms. Laba has over 18 years of experience in the life sciences and over 25 years of experience in finance and operations.
Priya Karmali, Senior Director of Pharmaceutical DevelopmentPriya Karmali is Senior Director of Pharmaceutical Development at Arcturus Therapeutics Ltd. Dr. Karmali joined Arcturus in 2015 and is responsible for research and development efforts for LUNAR™ technology, Arcturus’ lipid mediated nucleic acid delivery system. She has over 15 years of experience in the field of lipid-based drug delivery systems from discovery to development. Prior to Arcturus, Priya was Associate Director of Formulation Development at Regulus Therapeutics where she led drug product development efforts for miRNA therapeutic drugs currently in various stages of clinical trials. Prior to joining Regulus, Priya was a Principal Scientist at Nitto Denko where she led formulation development efforts for their Vitamin A targeted siRNA lipid nanoparticle for treatment of liver fibrosis. Dr. Karmali has a Ph.D. in Chemistry from the Indian Institute of Chemical Technology where she specialized in development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She is an author or inventor on over 35 scientific publications and patents.
Joseph E. Payne, is President, Chief Executive Officer and Chairman of the Board for Arcturus Therapeutics, Inc. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing nanoparticle delivery technologies.
Pad Chivukula, Ph.D., is Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology.
February 12, 2018
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
February 2, 2018
Arcturus Therapeutics Appoints Mark Herbert as Interim President
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics